Adjuvant intraarterial lipiodol or131I-lipiodol after curative treatment of Hepatocellular carcinoma: A prospective randomized trial

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 877-883

  Dumortier, Jérôme ^a,b   Decullier, Evelyne ^c,d   Hilleret, Marie Noëlle ^e   Bin Dorel, Sylvie ^c,d   Valette, Pierre Jean ^a,b   Boillot, Olivier ^a,b   Partensky, Christian ^a,b   Letoublon, Christian ^e,f   Ducerf, Christian ^b,g   Leroy, Vincent ^e,f   Vuillez, Jean Philippe ^f,h   Borson Chazot, Françoise ^b,c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d EAM Santé Individu Soci et É   (France)

^e HÔPITAL MICHALLON   (France)

^f UNIV GRENOBLE ALPES   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adjuvant therapy; Hepatocellular carcinoma; Recurrence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE LIPIODOL I 131; UNCLASSIFIED DRUG; ETHIODIZED OIL; RADIOACTIVE IODINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG LABELING; DRUG SAFETY; FEMALE; HEMATOMA; HUMAN; INJECTION PAIN; ISOTOPE LABELING; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; ADJUVANT CHEMORADIOTHERAPY; ADVERSE EFFECTS; AGED; CARCINOMA, HEPATOCELLULAR; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMORADIOTHERAPY, ADJUVANT; ETHIODIZED OIL; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903180198     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.131367     Document Type: Article

References (17)

1. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008;48:137-145. (Pubitemid 351980469)
2. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 1985;56:918-928. (Pubitemid 15228292)
3. Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 1995;22:522-526.
4. Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 1993;18:1121-1126. (Pubitemid 23320442)
5. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996;111: 720-726. (Pubitemid 26293238)
6. Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38:286-295.
7. Ahmadzadehfar H, Sabet A, Wilhelm K, Biersack HJ, Risse J. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246-252.
8. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797-801. (Pubitemid 29110405)
9. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial - update on 5-year and 10-year survival. Ann Surg. 2008;247:43-48.
10. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-207. (Pubitemid 36169630)
11. Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg. 2000;135:1298-1300.
12. Boucher E, Corbinais S, Rolland Y, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology. 2003;38:1237-1241. (Pubitemid 37314832)
13. 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49:362-366.
14. Chua TC, Saxena A, Chu F, et al. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Int J Clin Oncol. 2011;16:125-132.
15. 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med. 2004;45:612-618.
16. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19:951-959.
17. Memon K, Kulik L, Lewandowski RJ, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73-80.